A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
We focused on the relationship between variation in the IRES of hepatitis C virus (HCV) genotype 1b and clinical outcome, since the internal ribosome entry site (IRES) has a comparatively low heterogeneity and it might be easy to find unique substitutions. Patients infected with HCV were selected using strict criteria, and unique mutations in the IRES were extracted by the subtraction of common mutations. We found that most mutations accumulated in domain III (dIII) of IRES in sustained virological responders (SVRs) and non-SVRs before therapy. However, these mutations were exclusively observed in domain II (dII) in non-SVR at 2 weeks after the start of therapy.
Ogata
Kei
K
Division of Infectious Diseases, Department of Infectious Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, Japan.
Kashiwagi
Takahito
T
Iwahashi
Jun
J
Hara
Koyu
K
Honda
Haruhito
H
Ide
Tatsuya
T
Kumashiro
Ryukichi
R
Kohara
Michinori
M
Sata
Michio
M
Watanabe
Hiroshi
H
Hamada
Nobuyuki
N
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D006526:Hepatitis C / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D007372:Interferons / Q000494:pharmacology* / Q000627:therapeutic use; D009154:Mutation / Q000187:drug effects*; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D012254:Ribavirin / Q000494:pharmacology* / Q000627:therapeutic use; D012270:Ribosomes / Q000378:metabolism
D000998:Antiviral Agents; D012367:RNA, Viral; D012254:Ribavirin; D007372:Interferons